NeutralLOW severityHealthcare & Pharma67d ago

Johnson & Johnson receives CE mark for new 2-week contact lens

Johnson & Johnson receives CE mark for new 2-week contact lens — $JNJ one-month chart
$JNJ daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about JNJ. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · Johnson & JohnsonEvent risk Low

Nothing reported about Johnson & Johnson across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 26% a year
Now $282.55Week $272.30–$292.80 (±3.6%)Month $261.54–$303.56 (±7.4%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
  • How the stock is trading: $JNJ -1.12% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.

Where the stock stands

Johnson & Johnson ($JNJ) fell 1.12% to $282.55 in the latest session. Over the past month it is up 11.3%. It now sits 2.7% under the 52-week high of $290.25 and 44% above the year's low of $195.90, close to the top of its range. Its range over the year spans 48%, which is moderate.

What the filings say

In its latest report (10-Q, filed Oct 21, 2026), $JNJ earned $210.0M over the quarter to Sep 27, 2026 on revenue of $25.40B (+0.4% QoQ). Operations brought in $18.85B of cash over the nine months to Sep 27, 2026; after capital spending, free cash flow was $15.12B. It carried $37.80B of debt against $16.91B of cash on Sep 27, 2026 — net debt of $20.89B. Its most recent filings before this story: 8-K on Aug 4, 2026, 8-K on Jul 29, 2026, 8-K on Jul 28, 2026. Figures are as filed with the SEC; the $JNJ page has the full statements.

How much coverage it is getting

This story is more than a month old. Since then Wook has filed 11 newer stories on Johnson & Johnson in the last 30 days, 1 of them this week. By their wording, 18% read bullish, 55% neutral and 27% bearish.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

Coming up

$JNJ earnings in 71 days — on the calendar well before this story broke.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $JNJ page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $JNJ: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on September 10, 2026. $JNJ has moved +6.08% ($266.35 to $282.55). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy